Evidence map›Paper›PMID 41928344›Full record

ArticleDiabetology & metabolic syndrome2026

Comparative performance of FINDRISC and IDRS in screening for type 2 diabetes risk among Yemeni university students.

Abdulsalam Al-Shami, Lina Qasem, Mufeed Baddah, Sami Kahtan

Abstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abdulsalam Al-ShamiDepartment of Clinical Biochemistry, Faculty of Medicine and Health Sciences, Taiz University, Taiz, Yemen. dralshami77@gmail.com.ORCID http://orcid.org/0000-0001-8880-5919
Lina QasemDepartment of Medical Biochemistry, Faculty of Medicine and Health Sciences, Amran University, Amran, Yemen.
Mufeed BaddahDepartment of Clinical Biochemistry, Faculty of Medicine and Health Sciences, Taiz University, Taiz, Yemen.
Sami KahtanDepartment of Clinical Biochemistry, Faculty of Medicine and Health Sciences, University of Aden, Aden, Yemen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) is a leading cause of death worldwide.To address the rise of T2DM, it might be more effective to create and validate a targeted risk scoring system for specific populations. This study aimed to evaluate and compare the diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) and the Indian Diabetes Risk Score (IDRS) in screening for dysglycemia (i.e. the presence of prediabetes or T2DM) and to identify the factors associated with T2DM risk among young medical students at the Faculty of Medicine, Taiz University, Yemen.

methodsA cross-sectional study was conducted among 200 medical students without a prior history of diabetes at Taiz University. The FINDRISC and IDRS questionnaires were used along with fasting blood sugar to estimate the efficacy of both risk scores in screening dysglycemia. Descriptive statistics and the chi-square test were used, with P < 0.05 regarded as statistically significant. The diagnostic accuracy of FINDRISC and IDRS was compared using the area under the receiver operating characteristic curve (AUC-ROC). Sensitivity, specificity, and the best cut-off to detect dysglycemia were calculated for each risk score. The best cutoffs were determined by maximizing the Youden Index.

resultsof the 200 participants, 10.5% and 1.5% were diagnosed with prediabetes and T2DM, respectively, where females had a higher prevalence than males for both outcomes (P < 0.001). The screening performance for dysglycemia differed significantly between the two tools (P < 0.001). The FINDRISC achieved a larger AUC-ROC (0.782; 95% CI: 0.68–0.88) with ≥ 9 as an optimal cut-off (sensitivity: 67.0%, specificity: 80.1%, and Youden index: 0.44) compared to that of IDRS (0.671; 95% CI: 0.56–0.78) with ≥ 45 as an optimal cut-off (sensitivity: 46.0%, specificity: 80.0%, Youden Index: 0.25). A Bland-Altman plot indicated adequate agreement at lower risk scores; however, significant divergence at higher risk scores, suggesting the tools are not interchangeable.

conclusionThe FINDRISC demonstrated acceptable diagnostic utility and significantly outperformed the IDRS in this young Yemeni population;with its effectiveness increasing at higher risk scores. This makes it the preferred initial screening tool for identifying individuals with dysglycemia, especially in resource-constrained environments, such as the Yemeni setting. However, due to its modest standalone sensitivity, we recommend that individuals with a FINDRISC score ≥ 9 should undergo definitive laboratory testing to confirm the diagnosis and ensure early detection of dysglycemia.

Indexed as

Diagnostic accuracyDysglycemiaFINDRISCIDRSType 2 diabetes mellitusYemen

Identifiers

PMID41928344
PMCPMC13063733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.